ReviewPeerJ2025
Mechanisms of NLRP3 inflammasome in pathogenesis and progression of inflammation-related gastrointestinal diseases.
Review in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammasome-Interferon Convergence in Elite HIV Controllers and Autoimmune Diseases: A Critical Integrative Reflection.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inflammasome is a novel component of the innate immune response. It plays a crucial role in the pathogenesis and progression of inflammation-related gastrointestinal diseases. Among various inflammasomes, the NLR family pyrin domain containing 3 (NLRP3) inflammasome is one of the most extensively studied. Increasingly, researchers are exploring its roles and mechanisms, particularly in inflammation-immune-related diseases. As a result, a review paper is demanded to review and summarize the previous and latest studies on the role and mechanisms of NLRP3 inflammasome in pathogenesis and progression of inflammation-related gastrointestinal diseases. This review comprehensively elaborates on the biological characteristics of the NLRP3 inflammasome, including its assembly and activation mechanisms. Additionally, it emphasizes the roles and mechanisms of the NLRP3 inflammasome in common inflammation-related gastrointestinal diseases such as ulcerative colitis, Crohn's disease, pancreatitis, and non-alcoholic fatty liver disease (NAFLD). Furthermore, the application of NLRP3 inflammasome inhibitors in treating these diseases is discussed. Articles from PubMed and Web of Science on NLRP3 inflammasome, ulcerative colitis, Crohn's disease, pancreatitis, and NAFLD were summarized to analyze the data and conclusions carefully to ensure the comprehensiveness, completeness, and accuracy of the review. This study aims to provide scholars engaged in research on gastrointestinal diseases with new directions for developing more effective therapeutics for inflammation-related gastrointestinal diseases by investigating the NLRP3 inflammasome's role in these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.